UniQure’s Huntington’s therapy fails to significantly slow disease progression, shares plunge

Uniqure Dives 35% On Another Shock For Its Gene Therapy

Uniqure stock plummeted Tuesday on a disappointing four-year update for its experimental gene therapy in patients with Huntington's disease.

UniQure’s Huntington’s therapy fails to significantly slow disease progression, shares plunge

Sept 29 (Reuters) - UniQure said its gene therapy for Huntington's ​disease fell short ‌of statistical significance on the main goal of slowing disease progression ‌in ​a four-year ⁠analysis, sending ⁠its U.S.-listed shares plummeting 55% in premarket ...

UniQure's gene therapy continues to slow Huntington's progression after four years

UniQure's gene therapy continues to slow Huntington's progression after four years. But the magnitude of the benefit waned compared to a similar analysis from a year ago.

UniQure sinks as Huntington's gene therapy appears to show waning benefit over time

UniQure's shares {$QURE} were rocked Tuesday morning after the company revealed its experimental Huntington’s disease gene therapy may have less benefit than originally thought. In an additional year of follow-up data, the experimental treatment

uniQure (QURE) Stock Crashes 48% on Disappointing Huntington's Trial Results

uniQure (QURE) stock plummeted 48% after AMT-130 gene therapy missed its statistical endpoint in new 48-month Huntington's disease trial data.

uniQure (QURE) Stock Plunges 48% After Huntington’s Drug Data Miss

TLDR uniQure stock fell 48% to $20.50 in premarket trading on Tuesday. The drop followed a new 48-month analysis of the Huntington’s disease therapy AMT-130. AMT-130 showed a 44% slowing of disease progression at 48 months, but the result did not clear the statistical bar. uniQure says its FDA...